KRAS and non-small cell lung carcinoma: Despite its initial challenges of being “undruggable”, several inhibitors that specifically bind KRAS-G12C have been developed and investigated in clinical trials, with sotorasib becoming the first treatment to gain approval for adults with stage IV NSCLC harboring a KRAS-G12C mutation as a second-line therapy [15,16,17,18,19].